Desvenlafaxine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis

Pharmacopsychiatry

Volumn 48, Issue 6, 2015, Pages 187-199

  Laoutidis, Z G ^a   Kioulos, K T ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

depression; desvenlafaxine; meta analysis; review; SNRI

Indexed keywords

DESVENLAFAXINE; DRUG METABOLITE; DULOXETINE; ESCITALOPRAM; PLACEBO; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADVERSE OUTCOME; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFICACY; DRUG MARKETING; DRUG TOLERABILITY; EFFECT SIZE; EMBASE; HIGH RISK POPULATION; HUMAN; MEDLINE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DESVENLAFAXINE SUCCINATE; HUMANS;

EID: 84940889244     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0035-1555879     Document Type: Review

References (31)

1. Cipriani A., Furukawa T. A., Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet: 2009; 373 746 758 10.1016/S0140-6736(09)60046-5
2. Deecher D. C., Beyer C. E., Johnston G. et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther: 2006; 318 657 665
3. Leucht S., Cipriani A., Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet: 2013; 382 951 962
4. Thase M. E., Kornstein S. G., Germain J. M. et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr: 2009; 14 144 154
5. Higgins JP T., Green S. Cochrane Handbook for Systematic Reviews of Interventions. In The Cochrane Library, Volume Issue 4. Chichester, UK John Wiley & Sons, Ltd; 2006
6. Friedrich J. O., Adhikari NK J., Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol: 2007; 7 5 10.1186/1471-2288-7-5
7. Furukawa T. A., Cipriani A., Barbui C. et al. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol: 2005; 20 49 52
8. Borenstein M., Hedges R. V., Higgins JP T. et al. Introduction to Meta-Analysis. West Sussex Wiley Edition: 2009
9. Neyeloff J. L., Fuchs S. C., Moreira L. B. Meta-analyses and forest plots using a Microsoft Excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes: 2012; 5 52 http://www.biomedcentral.com/1756-0500/5/52
10. Egger M., Davey Smith G., Schneider M. et al. Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ: 1997; 315 629 634
11. DeMartinis N. A., Yeung P. P., Entsuah R. et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry: 2007; 68 677 688
12. Liebowitz M. R., Yeung P. P., Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry: 2007; 68 1663 1672
13. Septien-Velez L., Pitrosky B., Padmanabhan S. K. et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol: 2007; 22 338 347
14. Boyer P., Montgomery S., Lepola U. et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol: 2008; 23 243 253
15. Lieberman D. Z., Montgomery S. A., Tourian K. A. et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol: 2008; 23 188 197
16. Liebowitz M. R., Manley A. L., Padmanabhan S. K. et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin: 2008; 24 1877 1890
17. Feiger A. D., Tourian K. A., Rosas G. R. et al. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr: 2009; 14 41 50
18. Tourian K. A., Padmanabhan S. K., Groark J. et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther: 2009; 31 1405 1423
19. Iwata N., Tourian K. A., Hwang E. et al. Efficacy and safety of desvenlafaxine 25 and 50mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract: 2013; 19 5 14
20. Liebowitz M. R., Tourian K. A., Hwang E. et al. Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry: 2013; 13 94
21. Clayton A. H., Tourian K. A., Focht K. et al. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry: 2014; Oct 28. [Epub ahead of print]
22. Kornstein S. G., Jiang Q., Reddy S. et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry: 2010; 71 1088 1096
23. Clayton A. H., Kornstein S. G., Dunlop B. W. et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry: 2013; 74 1010 1017
24. Dunlop B. W., Reddy S., Yang L. et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol: 2011; 31 569 576
25. Soares C. N., Thase M. E., Clayton A. et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause: 2010; 17 700 711
26. Schueler Y. B., Koesters M., Wieseler B. et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand: 2011; 123 247 265
27. Papakostas G. I., Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol: 2009; 19 34 40
28. Bridge J. A., Birmaher B., Iyengar S. et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry: 2009; 166 42 49
29. Coleman K. A., Xavier V. Y., Palmer T. L. et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr: 2012; 17 131 141
30. ACADIA Pharmaceuticals ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial. (Jun 16); 2008; Internet http://news.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=1166151
31. DrugBank 4.0: shedding new light on drug metabolism Law V., Knox C., Djoumbou Y. et al. Nucleic Acids Res: 2014; 42 D1091 D1097 PubMed ID: 24203711. Available from http://www.drugbank.ca/drugs/DB06731#references